Home › Funds › Uniplan Investment Counsel, Inc. › LGND

Uniplan Investment Counsel, Inc. position in LGND

LIGAND PHARMACEUTICALS INC · Health Care

Uniplan Investment Counsel, Inc. reported holding 35,176 shares of LGND (LIGAND PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$11.0M, representing 1.08% of its reported portfolio and ranking #20 among its reported holdings. Uniplan Investment Counsel, Inc. has disclosed LGND holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

Latest position (Q3 2026)35.18K sh
Reported value held$10.99M
Portfolio Weight1.08%
First reportedQ1 2024
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Uniplan Investment Counsel, Inc.'s LGND position evolved

Uniplan Investment Counsel, Inc. first disclosed a stake in LGND in Q1 2024 at 41,201 shares (US$3.0M). The position peaked in Q3 2026 at 35,176 shares, worth US$11.0M. Across 11 filings, Uniplan Investment Counsel, Inc. increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 35,176 shares valued at US$11.0M — an increase of 927 shares quarter over quarter.. Notable position changes include a 28% increase in Q4 2024 (shares fell 2% over the following quarter), a 33% trim in Q3 2025 (shares rose 7% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 41.20K $3.01M New
Q2 2024 49.62K $4.18M Add
Q3 2024 53.10K $5.32M Add
Q4 2024 68.16K $7.30M Add
Q1 2025 68.79K $7.23M Add
Q2 2025 62.95K $7.16M Reduce
Q3 2025 42.18K $7.47M Reduce
Q4 2025 42.36K $8.01M Hold
Q1 2026 40.19K $8.02M Reduce
Q2 2026 34.25K $10.83M Reduce
Q3 2026 35.18K $10.99M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LGND and 13F data

LGND (LIGAND PHARMACEUTICALS INC) is a Health Care company. 52 other funds we track also report a position in LGND — the largest reported positions include CONGRESS ASSET MANAGEMENT CO (US$205.7M), Chicago Capital, LLC (US$172.2M), Stephens Investment Management Group LLC (US$139.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LGND

All LGND fund holders →

FAQ

How long has Uniplan Investment Counsel, Inc. held LGND?

Uniplan Investment Counsel, Inc. has disclosed LGND holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

What is Uniplan Investment Counsel, Inc.'s current position in LGND?

As of Q3 2026, Uniplan Investment Counsel, Inc. holds 35.18K shares of LGND (LIGAND PHARMACEUTICALS INC), valued at $10.99M, representing 1.08% of its reported portfolio and ranking #20.

Has Uniplan Investment Counsel, Inc. been buying or selling LGND?

In the latest 13F filing (Q3 2026), Uniplan Investment Counsel, Inc. increased its position in LGND. The position peaked in Q3 2026 at 35.18K shares.

Which other funds hold LGND?

Other major institutional holders of LGND include CONGRESS ASSET MANAGEMENT CO, Chicago Capital, LLC, Stephens Investment Management Group LLC, among 52 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.